FOXP3 and carcinoma: When analyzed for regulatory T cells, the cases with concurrent low CSF-1R+ carcinoma cells and low FOXP3 iTILs exhibit the best outcome (HR 0.71, 95% CI 0.60–0.86; p = 0.001) (Figure 4B).